98556-09-3

Basic information

• Product Name: N-(2-broMo-5-nitrophenyl)forMaMide
• Synonyms: N-(2-broMo-5-nitrophenyl)forMaMide
• CAS NO: 98556-09-3
• Molecular Formula: C₇H₅BrN₂O₃
• Molecular Weight: 245.0302
• Mol File: 98556-09-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(2-broMo-5-nitrophenyl)forMaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-broMo-5-nitrophenyl)forMaMide(98556-09-3)
• EPA Substance Registry System: N-(2-broMo-5-nitrophenyl)forMaMide(98556-09-3)

Safety Data

• Hazardous Substances Data: 98556-09-3(Hazardous Substances Data)

Usage

General Description

N-(2-bromo-5-nitrophenyl)formamide is a chemical compound with the molecular formula C7H5BrN2O3. It is a formamide derivative that contains a bromine and a nitro group attached to a phenyl ring. N-(2-broMo-5-nitrophenyl)forMaMide is commonly used in organic synthesis as a reagent for the preparation of various pharmaceuticals and agricultural chemicals. It has been found to exhibit anti-inflammatory and antioxidant properties, and has been studied for its potential use in the treatment of various diseases. Additionally, it has also been investigated for its potential use as a dye intermediate and in the production of polymers.

Upstream product

• 64-18-6 formic acid 
• 10403-47-1 2-bromo 5-nitroaniline 

Downstream Products

• 2942-07-6 5-nitrobenzothiazole 
• 1123-93-9 5-aminobenzothiazole 
• 36894-61-8 N-(benzo[d]thiazol-5-yl)acetamide 
• 36894-62-9 N-phenylbenzo[d]thiazol-5-amine 
• 945912-69-6 N-(2-bromo-5-nitrophenyl)formimidoyl dichloride 

Relevant articles and documents

Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis

A previous publication from this lab (Patrick, et al. Bioorg. Med. Chem. 2016, 24, 2451-2465) explored the antitrypanosomal activities of novel derivatives of 2-(2-benzamido)ethyl-4-phenylthiazole (1), which had been identified as a hit against Trypanosoma brucei, the causative agent of human African trypanosomiasis. While a number of these compounds, particularly the urea analogues, were quite potent, these molecules as a whole exhibited poor metabolic stability. The present work describes the synthesis of 65 new analogues arising from medicinal chemistry optimization at different sites on the molecule. The most promising compounds were the urea derivatives of 2-aryl-benzothiazol-5-amines. One such analogue, (S)-2-(3,4-difluorophenyl)-5-(3-fluoro-N-pyrrolidylamido)benzothiazole (57) was chosen for in vivo efficacy studies based upon in vitro activity, metabolic stability, and brain penetration. This compound attained 5/5 cures in murine models of both early and late stage human African trypanosomiasis, representing a new lead for the development of drugs to combat this neglected disease.